drug · small molecule
lazertinib mesylate
Marketedupdated 3mo agoby $JNJ JOHNSON & JOHNSON🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and 1 investigational indication.
indications
investigational
NSCLC
targets
Epidermal growth factor receptor
all catalysts(3)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 19, 2029
~3.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Aug 1, 2041method-of-use (U-3985)US 11850248
- Aug 1, 2041method-of-use (U-3985)US 11850248
- Apr 13, 2041formulationUS 12138351
- Apr 13, 2041formulationUS 12138351
- May 21, 2040method-of-use (U-3985)US 11879013
- May 21, 2040method-of-use (U-3985)US 11879013
- Apr 18, 2038compositionUS 11453656
- Apr 18, 2038compositionUS 11453656
- Apr 18, 2038method-of-use (U-3985)US 11981659
- Apr 18, 2038method-of-use (U-3985)US 11981659
- Apr 18, 2038formulationUS 12318390
- Apr 18, 2038formulationUS 12318390
- Oct 13, 2035compositionUS 9593098
- Oct 13, 2035compositionUS 9593098
FDA exclusivities (2)
- Aug 19, 2029NCENew Chemical Entity (5y)3.0y
- Aug 19, 2029NCENew Chemical Entity (5y)3.0y
News(1)
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalTaiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…fiercebiotech · 4d ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that